Biotechnology News and Research

RSS

Delphi Genetics announces new license agreement for use of StabyExpress technology in food industry

Delphi Genetics SA has announced today a new license agreement for the use of the StabyExpress® technology in the food industry. The technology will be used for the production of enzymes for food processing.

17 Jun 2014

Affordable Care Act to have significant impact on patients with diabetes

The Affordable Care Act (ACA, also known as Obamacare) is dramatically changing health care delivery in the U.S. Specific parts of the new law, which will be phased in through 2020, will have a significant impact on patients with diabetes and prediabetes, as explored in a comprehensive Review article published in Diabetes Technology & Therapeutics, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers.

17 Jun 2014

Scientists identify novel approach to treating multiple sclerosis

Scientists in the University of Connecticut's Technology Incubation Program have identified a novel approach to treating multiple sclerosis (MS) using human embryonic stem cells, offering a promising new therapy for more than 2.3 million people suffering from the debilitating disease.

17 Jun 2014

Chikungunya virus puts some regions at risk of epidemic

For the first time, University of Texas Medical Branch at Galveston researchers were able to predict further adaptations of the chikungunya virus that recently spread from Africa to several continents that will likely result in even more efficient transmission and infection of more people by this virus strain.

17 Jun 2014

Fighting off illness causes sleep deprivation and affects memory

Sickness-induced insomnia is common because of link between brain and immune system. Fighting off illness- rather than the illness itself- causes sleep deprivation and affects memory, a new study has found.

13 Jun 2014

TxCell receives Certificate of GMP compliance for cell therapy manufacturing facility in France

TxCell SA, a biotechnology company developing innovative, personalized cell-based immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic inflammatory and autoimmune diseases, announces today that it has been granted Certificate of Good Manufacturing Practice (GMP) compliance for its cell therapy manufacturing facility in Besançon, France.

12 Jun 2014

Novel bone implants can keep germs at bay

Hospital germs can be fatal, since they are resistant to antibiotics. As a result, alternative methods of defense against bacteria are in demand. Fortunately, a German-French research team has been able to develop bone implants that keep the germs at bay.

11 Jun 2014

New research collaboration aims to develop better therapies for autoimmune diseases

Seattle Children's Research Institute and biotechnology company Kineta, Inc. today launched the Alliance for Children's Therapeutics (ACT), a first-of-its-kind pediatric research and funding collaboration designed to speed development of new medications for children and teens with lupus nephritis and other autoimmune diseases like multiple sclerosis, Type 1 diabetes and rheumatoid arthritis.

11 Jun 2014

Healthcare Corporate Access Day to be held on June 24, 2014

ROTH Capital Partners, a full-service investment bank focused on serving emerging growth companies and their investors, today announced that it will host its Healthcare Corporate Access Day on Tuesday, June 24, 2014, at the Dorchester Hotel in London, U.K.

11 Jun 2014

RBCC's injectable technology poised to improve use of addiction treatment drug

Rainbow Coral Corp. received a boost recently when researchers reported that a medication that could help tens of thousands of alcoholics quit drinking are underused.

11 Jun 2014

New framework for monitoring oral cancer development, progression, recurrence

Each year, approximately 22,000 Americans are diagnosed with oral cancer. The five-year survival rate of 40% in the U.S. is one of the lowest of the major cancers, and it has not improved in the past 40 years.

11 Jun 2014

Northwest Biotherapeutics initiates Phase III trial of DCVax-L in Germany

Northwest Biotherapeutics, a biotechnology company developing DCVax personalized immune therapies for solid tumor cancers, announced today that it has initiated the Phase III trial of DCVax-L in Germany.

10 Jun 2014

Alnylam announces new pre-clinical results with DC for ALN-CC5 to treat complement-mediated diseases

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today new pre-clinical results with its Development Candidate (DC) for ALN-CC5, a subcutaneously administered investigational RNAi therapeutic targeting complement component C5 in development for the treatment of complement-mediated diseases.

10 Jun 2014

Auxogyn receives clearance from FDA for Eeva System

Auxogyn, Inc. a leader in women's reproductive health, today announced that its first product, the Eeva System, received clearance from the U.S. Food and Drug Administration through its de novo classification process, a regulatory pathway for select novel, low- to moderate-risk medical devices that are first-of-a-kind.

10 Jun 2014

$arGEN-X partner with LLS to develop ARGX-110 for patients with refractory WM$

arGEN-X partner with LLS to develop ARGX-110 for patients with refractory WM

arGEN-X, a clinical stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today announced it has entered into a partnership with The Leukemia & Lymphoma Society (LLS) in which both parties will contribute to the funding of a Phase 2 clinical study of the Company's lead candidate, ARGX-110, in patients with refractory Waldenström's macroglobulinemia (WM).

10 Jun 2014

Synthetic, Enterome partner to study effects of beta-lactam antibiotics on gastrointestinal microflora

Synthetic Biologics, Inc., a developer of novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases, and Enterome Bioscience SA, a pioneer in the development of innovative disease management solutions based on a deep understanding of the gut microbiome, today announced that they have entered into an agreement to conduct metagenomic research on the effects of beta-lactam antibiotics on the gastrointestinal microflora (microbiome) of human patients.

10 Jun 2014

Accelera signs agreement to complete preclinical studies of Cellectis' UCART19

Cellectis, a leader of allogeneic CAR T-cell therapies, and Accelera, the preclinical CRO (Contract Research Organisation) within the Nerviano Medical Sciences Group, recently signed an agreement to complete the preclinical studies of Cellectis' advanced product candidate, UCART19.

9 Jun 2014

Research finding could lead to new strategies for malaria control

Researchers have found the first evidence of an intercellular bacterial infection in natural populations of two species of Anopheles mosquitoes, the major vectors of malaria in Africa. The infection, called Wolbachia, has been shown in labs to reduce the incidence of pathogen infections in mosquitoes and has the potential to be used in controlling malaria-transmitting mosquito populations.

6 Jun 2014

Dendreon shareholders call for annual elections to increase board independence and accountability

Eighty-four percent (84%) of votes cast by shareholders at Dendreon voted in favor of a proxy proposal calling for annual election of board members, a strategy - which if enacted - would increase board independence and accountability.

6 Jun 2014

Verde Media secures construction site in Asia with joint venture partner, Phoenix Energy

Verde Media Group Inc. through its Biotechnology Division (VMBD) is pleased to announce that it has secured its 40,000-square-foot construction site in Asia with joint venture partner, Phoenix Energy.

6 Jun 2014